Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2043  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (1,257 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 »  Materials and Me...
 » Results
 » Discussion
 » Conclusion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed3207    
    Printed45    
    Emailed0    
    PDF Downloaded28    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
REVIEW ARTICLE
Year : 2018  |  Volume : 66  |  Issue : 2  |  Page : 362-367

Patterns of care and survival outcomes in patients with an extraventricular neurocytoma: An individual patient data analysis of 201 cases


Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India

Date of Web Publication15-Mar-2018

Correspondence Address:
Dr. Supriya Mallick
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.227262

Rights and Permissions

 » Abstract 


Introduction: Extraventricular neurocytoma is a rare neuronal tumor arising outside the ventricles. However, because of its rarity, its optimum treatment remains undefined.
Materials and Methods: We intended to perform an individual patient data analysis to examine the patterns of care and prognostic factors involved in the treatment of extraventricular neurocytomas. PubMed, SCOPUS, and Google Scholar were searched with the following MeSH terms: “Neurocytoma, Extra ventricular neurocytoma, Spinal neurocytoma AND treatment, Survival” to find all possible publications pertaining to EVN.
Results: From 108 publications, we retrieved 201 patients of extraventricular neurocytoma. Their median age was 30 years (range: 0.6–78 years). Sixty seven patients were in the pediatric (age ≤20 years) age group. There was a bimodal age distribution. Surgical details were available for 132 cases, and 51.5% underwent a gross total resection whereas 41.7% underwent a subtotal resection. Adjuvant radiation was used in 40% cases. For the entire cohort, the median progression free survival was 77 months (53.3–100.7). However, we could not find an impact of any of the prognostic factors on survival.
Conclusion: An extraventricular neurocytoma is a very rare disease with varied presentations and different sites of origin. Gross total resection remains the standard of care. Adjuvant radiation may be used for salvage. However, radiation therapy after subtotal resection of an atypical neurocytoma may be administered.


Keywords: Extraventricular, neurocytoma, pattern of care, radiotherapy, surgery
Key Message: Presence of an extraventricular neurocytoma is extremely rare. Its outcome is inferior to that of the more commonly encountered intraventricular neurocytoma. Gross total excision is the standard of care and adjuvant radiation may be employed for incompletely resected and atypical extraventricular neurocytomas, particularly of spinal location.


How to cite this article:
Mallick S, Benson R, Rath GK. Patterns of care and survival outcomes in patients with an extraventricular neurocytoma: An individual patient data analysis of 201 cases. Neurol India 2018;66:362-7

How to cite this URL:
Mallick S, Benson R, Rath GK. Patterns of care and survival outcomes in patients with an extraventricular neurocytoma: An individual patient data analysis of 201 cases. Neurol India [serial online] 2018 [cited 2019 Aug 19];66:362-7. Available from: http://www.neurologyindia.com/text.asp?2018/66/2/362/227262


Neurocytoma is a rare neuronal tumor recognized by the World Health Organization (WHO) as a separate entity in 2007. Neurocytomas more commonly arise from the ventricles and are known as central neurocytomas, with an estimated incidence of 0.1–0.5% of all primary brain tumors.[1],[2] However, in the recent years, neurocytomas have been reported to arise from the brain parenchyma as well as from the spinal cord and are termed as extraventricular neurocytomas (EVNs).[3] EVNs comprise only a handful of cases reported so far, and in different series, they comprise 10% of total neurocytomas.[4] Spinal neurocytomas (SNC) are extremely rare tumors with only 35 cases reported so far. In general, a neurocytoma is considered as a low-grade tumor and surgical excision is considered adequate with the aim of achieving gross total resection (GTR). However, even after complete resection, many patients experience recurrence of the tumor.[1] EVNs and SNCs pose a greater challenge in management because of the difficulty in achieving complete surgical resection. Treatment options for EVNs and SNCs are derived from case reports and small case series, making it difficult to decide the optimum treatment protocol. However, most centers recommend adjuvant radiation therapy to optimize tumor control and survival. Hence, we intended to perform an individual patient data analysis to find the patterns of care, failure patterns, and prognostic factors, as well as to derive a possible treatment algorithm for EVN.


 » Materials and Methods Top


Search methodology

We performed a comprehensive search of PubMed, SCOPUS, and Google Scholar with the following MeSH terms: “Neurocytoma, Extra ventricular neurocytoma, Spinal neurocytoma AND Treatment, Survival” to find all possible publications pertaining to EVN. We also conducted a detailed reference search of the available articles to retrieve missing articles and conducted a Google search to find any additional publications. After a thorough search, duplicates were removed and the remaining articles were examined in detail. Articles that furnished the basic demography, treatment details, and survival information were included in the present analysis. A total of 108 articles were found eligible for the analysis. Individual patient data were tabulated in an excel chart under the headings: age, gender, surgery, type of surgery, radiation and type of radiation, chemotherapy, recurrence, duration of progression free interval, and death. [Figure 1] depicts data synthesis from the eligible studies.
Figure 1: PRISMA flow diagram depicts the data synthesis from the eligible studies

Click here to view


Statistical analysis

The data were analyzed; categorical variables were summarized as frequency and percentage and quantitative variables as median and range. Kaplan–Meier method was used for survival analysis. Univariate analysis was performed to find the impact of age, gender, type of surgery, use of radiation, and use of chemotherapy on survival outcomes. A P value of <0.05 was taken as significant. The Statistical Package for the Scoial Sciences, version 16 (IBM, USA) was used for all statistical analyses.


 » Results Top


Demography

A total of 201 cases from 108 publications were found eligible for analysis. Age was reported in 187 cases. The median age for the entire cohort was 30 years (range: 0.6–78 years); 67 patients were in the pediatric (≤20 years) age group. There were two prominent peaks in the second and fifth decade, in which the incidence was relatively higher [Figure 2]. Gender was reported in 185 cases with a mild male preponderance (97 males and 88 females). Twenty-eight percent of the patients had a tumor in the frontal lobe. This was followed by a tumor in the temporal lobe (18%), thoracic spine (9%), parietal lobe (8%), cervical spine (7%), and cerebellum (7%). The site distribution is depicted in [Figure 3]. Seizure was the most common presenting symptom seen in 35% patients, followed by headache in 31% patients. For SNCs, a total of 35 cases were found eligible for the analysis. The median age for SNCs was 33 years (range: 6–67 years), and the male:female ratio was 1.2:1. A total of 48.57% of the patients with a SNC had the tumor in the thoracic spine. This was followed by a tumor in the cervical spine in 37.1% patients. Radiological features were reported in 26 cases. Tumors were heterogeneously enhancing in 18 cases (69.2%) whereas the rest were homogenously enhancing. In twenty-two (84.6%) patients, the tumors had a foci of calcification, of which 13 had tumor in the frontal lobe. Nine (13.4%) patients of the pediatric age group had calcification in their tumors. Details of the patient characteristics have been described in [Table 1].
Figure 2: Age distribution of patients with an extraventricular neurocytoma showing two prominent peaks in the second and fifth decade

Click here to view
Figure 3: Site distribution of the extraventricular neurocytomas

Click here to view
Table 1: Demographic features and patterns of care in patients with EVN

Click here to view


Treatment details

Surgical details were available for 132 cases; 51.5% underwent a gross total resection (GTR), whereas 41.7% underwent a subtotal resection (STR). For SNC, 11 (31.4%) patients underwent a GTR whereas 19 (54.3%) patients underwent a STR. The MIB labeling index was reported in 88 cases with the median MIB labeling index being 5 (range: 1–60). Out of 85 patients in whom the grade was reported, 20 (23.5%) patients had a grade I tumor, whereas 63 (74.1%) had a grade II tumor. Interestingly, two cases were reported to be grade III tumors. Information regarding adjuvant radiation was available for 102 cases. Out of the 102 cases, 41 (40.2%) received radiation and the rest were treated with surgery alone. The dose of adjuvant radiation varied widely from 43.2–64 Gy, with the median dose being 54 Gy. Two patients received gamma knife radiosurgery at a dose of 20 Gy. One patient additionally received craniospinal radiation. Twelve out of the 41 patients experienced recurrence even after radiation. One patient experienced CSF dissemination after radiation and another had cerebellar metastasis.

Only 5 (2.5%) patients received chemotherapy as a part of the adjuvant treatment. Temozolomide was the most common agent used in 2 cases. Interestingly, even after chemotherapy, 2 patients experienced recurrence. One of the patients with a recurrent tumor had CSF dissemination as well.

Survival outcome

The median follow-up was 16 months (1–276 months). The median progression free survival (PFS) was 77 months (53.3–100.7) for the entire cohort, whereas the median PFS for pediatric EVNs was 180 months (0–385.6) [Figure 4]. However, a univariate analysis could not find any impact of gender, type of surgery (GTR vs. STR), use of adjuvant radiation or chemotherapy, MIB labeling index, and grade, on the survival of the patients with an EVN.
Figure 4: Progression free survival for the entire cohort and for pediatric ventricular neurocytoma.

Click here to view


Pattern of recurrence and salvage treatment

The status at last follow-up was recorded in 117 cases (58.2%). Recurrence was reported in 33 cases. Interestingly, 2 patients with a primary tumor in the brain had CSF dissemination, and two patients with a spinal primary tumor had cerebellar dissemination. Salvage treatment was recorded for 13 out of 33 recurrent cases. Four patients underwent salvage re-surgery alone; 2 patients received salvage radiation alone, 2 received salvage surgery with radiation, whereas 1 patient received salvage surgery with radiation, and another one underwent salvage surgery, radiation therapy and temozolomide administration.


 » Discussion Top


The present study aimed to examine the patterns of care for EVNs across the globe and at the same time find the possible optimum treatment for these tumors. EVNs were reported to arise in a wide area of the central nervous system (CNS). However, the enthusiasm to report such cases leaves out important disease- and treatment-related information posing a significant challenge in interpreting data. Majority of the reported cases lacked survival information, which is a barrier for commenting on survival. Despite limitations, we searched for all possible publication of EVNs till June 2016. The present analysis found that EVNs comprise approximately 15% of all neurocytomas affecting all age groups.[2] In an interesting revelation, we found EVNs to have two distinct peaks in the second and fifth decades, and this finding in the context of central neurocytomas has not been reported till date. Though these tumors arise across the entire CNS, a quarter of the cases are located in the frontal lobe and 18% are located in the temporal lobe. Interestingly, SNCs comprise only 17.4% of all EVNs. Due to their varied locations, these tumors present with a wide array of symptoms, with seizure being the most commonly found symptom in nearly one-third of the cases, followed by headache. Notably, tumors located in the neocortical temporal lobe or mesial temporal lobe present with seizures of a different character and pose a diagnostic challenge. This reflects the need to keep EVNs as an important entity in the differential diagnosis of lesions in young patients presenting with seizures. However, the majority of spinal tumors presented with sensory or motor deficit. Radiologically, most patients presented with a solid and cystic mass with heterogeneous contrast enhancement. Calcification within the tumor was noted in a higher frequencyof patients. These radiological features highlight the importance of keeping an EVN as a differential diagnosis, along with an oligodendroglioma, anaplastic ganglioglioma, and other epileptogenic tumors, among young patients.

Surgery has long been advocated as the standard of care for neurocytomas and the same has been reported for EVNs.[5] A GTR is considered to be the cornerstone of treatment as in all other low-grade CNS tumors. However, because of its proximity to critical structures and an eloquent location, SNCs pose a challenge for neurosurgeons attempting to achieve GTR. Hence, many patients undergo STR or biopsy only. This was very clear in the present analysis as only half of the patients underwent GTR and 7% underwent biopsy only. This was further emphasized by the fact that GTR reduced to 31% for SNCs.

Being a low-grade tumor with a long tumor-doubling time, GTR is considered optimum for a neurocytoma. However, patients with atypical features and a subtotal resection have been reported to experience a high rate of recurrence, and adjuvant radiation is advocated by authors to improve disease control.[6] Various series have reported an excellent recurrence-free survival after GTR.[1] As EVNs are often surrounded by brain parenchyma, it is difficult to achieve GTR; this is equally true for SNCs.[4] Recurrences are common and could be as high as 50–60% in patients with a subtotal resection.[1] In the present analysis, 21 (10.4%) out of 64 cases where a STR had been achieved, experienced a recurrence, but only 10 (7.5%) out of 68 cases where a GTR had been achieved experienced a recurrence. This reflects the importance of GTR as well as the possible benefit of adding adjuvant therapy in further managing patients who have undergone a STR.

EVNs are associated with a poor outcome compared to the central neurocytoma and this fact further emphasizes the need for adjuvant therapy.[1] However, it should be noted that EVNs are found in close proximity to critical areas of the brain rendering GTR often difficult. In addition, infiltrations in the brain parenchyma make it difficult to achieve GTR and recurrence is expected. These recurrences are difficult to salvage with surgery as the location precludes a re-surgery. Hence, adjuvant radiation appears to have an important role for these patients with STR. Rades et al., reported a significantly improved outcome in patients with a neurocytoma with STR treated with or without radiation.[5] The authors had earlier reported a 100% local control in neurocytomas, whereas only a 75% local control was achievable in EVNs, when treated with adjuvant radiation after a STR.[6] These small studies are prone to have a bias and cannot form level 1 evidence; however, they should be considered as hypothesis generating studies.

Though with the current evidence, it is difficult to recommend adjuvant radiation to all patients, it appears logical to add adjuvant radiation in patients who underwent subtotal excision, especially if the tumor had been located in eloquent locations, as a second look surgery on further progression would not be possible in these tumors. The patterns of care also support these findings, as adjuvant radiation has more frequently been advocated in patients with STR. Radiation therapy may play a definite role in salvaging patients who have had a recurrence after surgery in the post-resection setting.[2],[7],[8]

There is no clear consensus on the radiation target volume. However, as these lesions are usually low-grade tumors, it is reasonably safe to extrapolate the data from that of low-grade gliomas. Fluid attenuated inversion recovery abnormality with or without a margin may be included in the clinical target volume. A conformal radiation delivery technique is preferred to avoid irradiation of the normal brain tissue outside the target volume. A wide dosage schedule has been used in the published literature, but a dose of 50.4 to 54 Gy at conventional fractionation is most commonly practiced.[6],[9] Patients should be explained the possible occurrence of long-term neurocognitive effects and the risk of second malignancies, as these patients are expected to survive long.[10]

The role of chemotherapy has not been studied in this rare tumor, and in the present analysis also, less than 3% received chemotherapy.[11],[12],[13],[14] As these tumors generally are diagnosed as grade I or II tumors, the role of adjuvant chemotherapy is doubtful. However, it may be used in a case-to-case basis in patients with recurrent tumors when other options of salvage therapy are exhausted. The optimal regimen and the number of cycles to be used are still disputed. However, a few case reports show a modest response with temozolomide. Chemotherapy, therefore cannot be recommended as an adjuvant treatment for the treatment of EVNs with the available evidence. [Table 2] summarizes all case series of EVNs, highlighting their demography, differences in patterns of care, and survival reporting.[1],[4],[12],[15],[16],[17],[18],[19],[20],[21] A possible treatment algorithm for the management of EVNs is given in [Figure 5].
Table 2: Summary of the published series of EVNs

Click here to view
Figure 5: Treatment algorithm for the management of extraventricular neurocytomas

Click here to view


The present analysis has several limitations. First, most studies did not cite all relevant information pertaining to the cases. The majority of cases were reported as case reports so adjuvant treatment, follow-up, recurrence, pattern of salvage, and overall survival information are not available. This prevents us from analyzing the overall survival. In addition, across different centers, the standard of care is variable, and hence, the pattern of care will be biased by the local practice prevalent. However, owing to its rarity, it is unrealistic to expect a uniform treatment protocol to be immediately established for EVNs. In this regard, this analysis plays a pivotal role in reporting the patterns of care and the prognostic factors influencing this rare disease.


 » Conclusion Top


EVN is a rare tumor with an inferior outcome compared to a neurocytoma. Surgery forms the cornerstone of therapy and GTR appears to confer a survival advantage. Very few patients received radiation and we could not correlate the impact of radiation with survival. Hence, GTR should remain the standard of care, and adjuvant radiation may be employed for incompletely resected and atypical EVNs, particularly of spinal location.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Brat DJ, Scheithauer BW, Eberhart CG, Burger PC. Extraventricular neurocytomas: Pathologic features and clinical outcome. Am J Surg Pathol 2001;25:1252-60.  Back to cited text no. 1
    
2.
Kim DG, Park CK. Central neurocytoma: Establishment of the disease entity. Neurosurg Clin N Am 2015;26:1-4.  Back to cited text no. 2
    
3.
Sweiss FB, Lee M, Sherman JH. Extraventricular neurocytomas. Neurosurg Clin N Am 2015;26:99-104.  Back to cited text no. 3
    
4.
Agarwal S, Sharma MC, Sarkar C, Suri V, Jain A, Sharma MS, et al. Extraventricular neurocytomas: A morphological and histogenetic consideration. A study of six cases. Pathology 2011;43:327-34.  Back to cited text no. 4
    
5.
Rades D, Schild SE. Treatment recommendations for the various subgroups of neurocytomas. J Neurooncol 2006;77:305-9.  Back to cited text no. 5
    
6.
Mallick S, Roy S, Das S, Joshi NP, Roshan V, Gandhi AK, et al. Role of adjuvant radiation in the management of central neurocytoma: Experience from a tertiary cancer care center of India. Indian J Cancer 2015;52:590-7.  Back to cited text no. 6
[PUBMED]  [Full text]  
7.
Han L, Niu H, Wang J, Wan F, Shu K, Ke C, et al. Extraventricular neurocytoma in pediatric populations: A case report and review of the literature. Oncol Lett 2013;6:1397-405.  Back to cited text no. 7
    
8.
Rades D, Schild SE, Fehlauer F. Defining the best available treatment for neurocytomas in children. Cancer 2004;101:2629-32.  Back to cited text no. 8
    
9.
Rades D, Schild SE. Value of postoperative stereotactic radiosurgery and conventional radiotherapy for incompletely resected typical neurocytomas. Cancer 2006;106:1140-3.  Back to cited text no. 9
    
10.
Rades D, Fehlauer F, Schild SE. Treatment of atypical neurocytomas. Cancer 2004;100:814-7.  Back to cited text no. 10
    
11.
Furtado A. Comprehensive review of extraventricular neurocytoma with report of two cases, and comparison with central neurocytoma. Clin Neuropathol 2010;29:134.  Back to cited text no. 11
    
12.
Patil A, Menon G, Easwer H, Nair S. Extraventricular neurocytoma, a comprehensive review. Acta Neurochir 2014;156:349-54.  Back to cited text no. 12
    
13.
Kim JH, Park KJ, Lee JH, Chung HS. Cerebral neurocytoma without ganglion cell differentiation. Acta Neurochir (Wien) 2005;147:309-12.  Back to cited text no. 13
    
14.
Cho M, Joo JD, Kim BH, Choe G, Kim CY. Hypothalamic extraventricular neurocytoma (EVN) in a pediatric patient: A case of EVN treated with subtotal removal followed by adjuvant radiotherapy. Brain Tumor Res Treat 2016;4:35-9.  Back to cited text no. 14
    
15.
Liu K, Wen G, Lv XF, Deng YJ, Deng YJ, Hou GQ, et al. MR imaging of cerebral extraventricular neurocytoma: A report of 9 cases. AJNR Am J Neuroradiol 2013;34:541-6.  Back to cited text no. 15
    
16.
Ahmad Z, Din NU, Memon A, Tariq MU, Idrees R, Hasan S. Central, extraventricular and atypical neurocytomas: A clinicopathologic study of 35 cases from Pakistan plus a detailed review of the published literature. Asian Pac J Cancer Prev 2016;17:1565-70.  Back to cited text no. 16
    
17.
El Demellawy D, Sur M, Ahmed AD, Provias J. Hemispheric extra-ventricular glioneurocytoma: A clinicopathological review with detailed immunohistochemical profile. Pathol Res Pract 2012;208:444-51.  Back to cited text no. 17
    
18.
Xiong Z, Zhang J, Li Z, Jiang J, Han Q, Sun S, et al. A comparative study of intraventricular central neurocytomas and extraventricular neurocytomas. J Neurooncol 2015;121:521-9  Back to cited text no. 18
    
19.
Yi KS, Sohn CH, Yun TJ, Choi SH, Kim JH, Han MH, et al. MR imaging findings of extraventricular neurocytoma: A series of ten patients confirmed by immunohistochemistry of IDH1 gene mutation. Acta Neurochir (Wien) 2012;154:1973-79  Back to cited text no. 19
    
20.
Giangaspero F, Cenacchi G, Losi L, Cerasoli S, Bisceglia M, Burger PC. Extraventricular neoplasms with neurocytoma features. A clinicopathological study of 11 cases. Am J Surg Pathol 1997;21:206-12.  Back to cited text no. 20
    
21.
Huang WY, Zhang BY, Geng DY, Zhang J. Computed tomography and magnetic resonance features of extraventricular neurocytoma: A study of eight cases. Clin Radiol 2013;68:e206-12.  Back to cited text no. 21
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow